Takeda Pharmaceutical Upgrades FY 2026 Outlook Following Strong First-Half Results
Takeda Pharmaceutical reported strong first-half financial results, highlighted by a non-GAAP earnings per share (EPS) of ¥308.00 and total revenue of ¥2,407 billion, representing an 8.4% increase year-over-year. The company also reported adjusted free cash flow of JPY 325.7 billion during this period. Driven by favorable foreign exchange impacts, Takeda has officially upgraded its full-year guidance for fiscal year 2026. This upward revision reflects the company's improved financial positioning and provides a more optimistic outlook for investors regarding long-term profitability and cash flow generation.
Coverage
- ROCKWELL AUTOMATION, INC - 8-K Filing
- Velocity Financial Non-GAAP EPS of $0.76 beats by $0.05, revenue of $102.1M beats by $49.24M
- BioMarin Pharmaceutical Non-GAAP EPS of $0.23 beats by $0.34, revenue of $1.03B beats by $10M
- Takeda Pharmaceutical Upgrades FY 2026 Outlook Following Strong First-Half Results